Background Liver metastases in patients with cancer are associated with poor survival. We
hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would
have antitumor activity in these patients. Patients and methods Patients with advanced
cancer and predominant liver metastases were treated on a phase I study of HAI oxaliplatin
in combination with systemic bevacizumab, with or without HAI or systemic fluorouracil
and/or leucovorin and/or cetuximab. Patients were divided into two treatment arms …

Background Liver metastases are associated with a poor prognosis. We investigated the use
of hepatic arterial infusion (HAI) of irinotecan combination therapy in patients with liver
metastases. Patients and methods Patients with histologically confirmed advanced cancer
with liver metastases that was refractory to standard therapy were eligible. A standard “3+ 3”
phase I study design was used to determine the dose-limiting toxicity (DLT) and the
maximum tolerated dose (MTD). Three cohorts were evaluated: HAI of irinotecan with …